AbCellera Biologics Inc (NASDAQ:ABCL)’s traded shares stood at 0.88 million during the latest session, with the company’s beta value hitting 0.42. At the last check today, the stock’s price was $3.10, to imply a decrease of -5.80% or -$0.19 in intraday trading. The ABCL share’s 52-week high remains $5.46, putting it -76.13% down since that peak but still an impressive 24.52% since price per share fell to its 52-week low of $2.34. The company has a valuation of $915.43M, with an average of 3.47 million shares in intraday trading volume over the past 10 days and average of 3.16 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for AbCellera Biologics Inc (ABCL), translating to a mean rating of 1.22. Of 9 analyst(s) looking at the stock, 0 analyst(s) give ABCL a Sell rating. 0 of those analysts rate the stock as Overweight while 2 advise Hold as 7 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.15.
AbCellera Biologics Inc (NASDAQ:ABCL) trade information
After registering a -5.80% downside in the latest session, AbCellera Biologics Inc (ABCL) has traded red over the past five days. The 5-day price performance for the stock is -2.23%, and -5.51% over 30 days. With these gigs, the year-to-date price performance is 5.78%. Short interest in AbCellera Biologics Inc (NASDAQ:ABCL) saw shorts transact 17.26 million shares and set a 5.37 days time to cover.
The extremes give us $5 and $5 for target low and target high price respectively. As such, ABCL has been trading -61.29% off suggested target high and -61.29% from its likely low.
AbCellera Biologics Inc (ABCL) estimates and forecasts
Looking at statistics comparing AbCellera Biologics Inc share performance against respective industry, we note that the company has underperformed competitors. AbCellera Biologics Inc (ABCL) shares are 17.84% up over the last 6 months, with its year-to-date growth rate lower than industry average at -15.69% against 16.00%. The rating firms project that company’s revenue will shrink -16.95% compared to the previous financial year.
Revenue forecast for the current quarter as set by 10 analysts is 7.58M. Meanwhile, for the current quarter, a total of 2 analyst(s) estimate revenue growth to 13.97M.Earnings reports from the last fiscal year show that sales brought in 9.2M and 9.95M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -17.62% before jumping 40.33% in the following quarter.
ABCL Dividends
AbCellera Biologics Inc has its next earnings report out in March. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
AbCellera Biologics Inc (NASDAQ:ABCL)’s Major holders
AbCellera Biologics Inc insiders hold 23.07% of total outstanding shares, with institutional holders owning 39.34% of the shares at 51.14% float percentage. In total, 39.34% institutions holds shares in the company, led by BAKER BROS. ADVISORS LP. As of 2024-06-30, the company held over 27.53 million shares (or 9.4033% of shares), all amounting to roughly $81.48 million.
The next major institution holding the largest number of shares is BAILLIE GIFFORD & CO with 21.91 million shares, or about 7.4852% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $64.86 million.
We also have iShares Biotechnology ETF and Vanguard Valley Forge Fds-Baillie Gifford Global Pos Impact Stock Fd as the top two Mutual Funds with the largest holdings of the AbCellera Biologics Inc (ABCL) shares. Going by data provided on Nov 30, 2024 , iShares Biotechnology ETF holds roughly 1.42 shares. This is just over 0.48% of the total shares, with a market valuation of $4.37 million. Data from the same date shows that the other fund manager holds a little less at 454.44, or 0.15% of the shares, all valued at about 1.4 million.
